BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
Copyright: ©Author(s) 2026.
World J Hepatol. Aug 27, 2026; 18(8): 123580
Published online Aug 27, 2026. doi: 10.4254/wjh.123580
Table 1 Baseline characteristics of patients in sub-study 1

All (n = 73)
HBV (n = 43)
ALD (n = 20)
HBV + ALD (n = 10)
Age (year), mean ± SD53.58 ± 9.1055.50 ± 9.0051.10 ± 9.5150.60 ± 10.24
Male61 (83.6)32 (74.4)19 (95.0)10 (100.0)
BMI (kg/m2)22.84 (3.28)22.12 (3.14)23.48 (3.36)23.57 (3.04)
Decompensation, n (%)59 (80.8)37 (86.0)13 (65.0)9 (90.0)
    Variceal bleeding54 (74.0)36 (83.7)9 (45.0)9 (90.0)
    Ascites needing treatment11 (15.1)4 (9.3)5 (25.0)2 (20.0)
    Hepatic encephalopathy1 (1.4)0 (0)1 (5.0)0 (0)
CSPH, n (%)63 (86.3)35 (81.4)18 (90.0)10 (100.0)
Etiology, n (%)
    HBV43 (58.9)NANANA
    ALD20 (27.4)NANANA
    HBV and ALD10 (13.7)NANANA
Child-Pugh class, n (%)
    Class A52 (71.2)35 (81.4)11 (55.0)6 (60.0)
    Class B18 (24.6)7 (16.3)7 (35.0)4 (40.0)
    Class C3 (4.1)1 (2.3)2 (10.0)0 (0)
Laboratory test, median (IQR)
    PLT (109/L)54.00 (11.00)72.00 (52.50)87.00 (54.75)72.00 (33.00)
    TBIL (μmol/L)19.60 (19.25)15.40 (11.10)27.90 (27.35)22.35 (22.90)
    Hb (109/L)101.00 (43.00)109.00 (46.00)101.00 (50.00)76.50 (47.50)
    ALT (U/L)25.00 (20.00)24.00 (15.00)29.00 (22.25)25.00 (13.00)
    AST (U/L)34.00 (24.50)30.00 (13.50)62.00 (73.75)40.00 (20.00)
    GGT (U/L)41.50 (67.50)35.00 (31.25)132.00 (194.00)27.00 (57.00)
    Alb (g/L)34.55 (6.50)37.20 (9.00)33.00 (5.70)33.20 (3.90)
    Cr (μmol/L)68.00 (21.00)72.00 (23.50)61.00 (15.25)65.50 (18.00)
    PT (seconds)15.90 (2.50)15.85 (2.70)15.95 (3.10)16.50 (2.10)
    INR1.27 (0.26)1.26 (0.27)1.30 (0.32)1.34 (0.23)


Write to the Help Desk